SEPN · Insider Trading
Septerna, Inc. Common Stock
Every open-market purchase and sale reported by SEPN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-19 | Elizabeth Bhatt | President and COO | MIXED | — | −$122.40K |
| 2026-09-10 | Rajiv Patni | Chief Medical Officer | A | +275,000 deriv. | — |
| 2026-09-03 | Daniel D. Long | SVP, Drug Discovery | MIXED | — | −$116.88K |
| 2026-08-14 | RA Capital Nexus Fund III, L.P. | Director | Sell | −1,493,000 | −$63.45M |
| 2026-08-14 | Third Rock Ventures V, L.P. | 10%+ Owner | Sell | +147,200 | +$7.40M |
| 2026-08-13 | Elizabeth Bhatt | President and COO | MIXED | — | −$955.34K |
| 2026-08-05 | Daniel D. Long | SVP, Drug Discovery | MIXED | — | −$105.72K |
| 2026-07-17 | Elizabeth Bhatt | President and COO | MIXED | — | −$108.73K |
| 2026-07-02 | Daniel D. Long | SVP, Drug Discovery | MIXED | — | −$105.33K |
| 2026-06-24 | Daniel D. Long | SVP, Drug Discovery | MIXED | — | −$451.21K |
| 2026-06-16 | Samira Shaikhly | Chief People Officer | MIXED | — | −$146.10K |
| 2026-06-03 | Samira Shaikhly | Chief People Officer | MIXED | — | −$160.57K |
| 2026-05-28 | Samira Shaikhly | Chief People Officer | MIXED | — | −$274.31K |
| 2026-04-17 | Elizabeth Bhatt | President and COO | MIXED | — | −$70.10K |
| 2026-03-04 | Samira Shaikhly | Chief People Officer | MIXED | — | −$1.85M |
| 2026-02-20 | Elizabeth Bhatt | President and COO | MIXED | — | −$88.62K |
| 2026-02-10 | Gil M Labrucherie | Chief Financial Officer | A | +125,000 deriv. | — |
| 2026-02-10 | Jae B. Kim | Chief Medical Officer | A | +125,000 deriv. | — |
| 2026-02-10 | Jeffrey Finer | Chief Executive Officer | A | +400,000 deriv. | — |
| 2026-02-10 | Daniel D. Long | SVP, Drug Discovery | A | +80,000 deriv. | — |
| 2026-02-10 | Elizabeth Bhatt | President and COO | A | +155,000 deriv. | — |
| 2026-02-10 | Samira Shaikhly | Chief People Officer | A | +80,000 deriv. | — |
| 2026-02-10 | Mark Andrew Wilson | Chief Legal Officer | A | +165,000 deriv. | — |
| 2026-02-10 | Uwe Klein | SVP, Biological Sciences | A | +80,000 deriv. | — |
| 2025-11-13 | Daniel D. Long | SVP, Drug Discovery | Sell | −3,501 | −$63.22K |
| 2025-09-29 | Keith Michael Gottesdiener | Director | A | +33,246 deriv. | — |
| 2025-08-19 | Uwe Klein | SVP, Biological Sciences | M | +23,008 | +$94.37K |
| 2025-08-11 | Daniel D. Long | SVP, Drug Discovery | A | +30,000 deriv. | — |
| 2025-08-11 | Samira Shaikhly | Chief People Officer | A | +30,000 deriv. | — |
| 2025-08-11 | Jeffrey Finer | Chief Executive Officer | A | +210,000 deriv. | — |
| 2025-08-11 | Elizabeth Bhatt | President and COO | A | +95,000 deriv. | — |
| 2025-08-11 | Jae B. Kim | Chief Medical Officer | A | +55,000 deriv. | — |
| 2025-08-11 | Gil M Labrucherie | Chief Financial Officer | A | +37,500 deriv. | — |
| 2025-08-11 | Uwe Klein | SVP, Biological Sciences | A | +30,000 deriv. | — |
| 2025-06-20 | Jeffrey K Tong | Director | A | +16,623 deriv. | — |
| 2025-06-20 | Jake Simson | Director | A | +16,623 deriv. | — |
| 2025-06-20 | Alan Ezekowitz | Director | A | +16,623 deriv. | — |
| 2025-06-20 | Abraham Bassan | Director | A | +16,623 deriv. | — |
| 2025-06-20 | Shalini Sharp | Director | A | +16,623 deriv. | — |
| 2025-06-20 | RA CAPITAL MANAGEMENT, L.P. | Director | A | +16,623 deriv. | — |
| 2025-06-20 | Bernard Coulie | Director | A | +16,623 deriv. | — |
| 2025-04-04 | Jeffrey Finer | CEO and President | M | +55,000 | +$151.80K |
| 2025-03-10 | Alan Ezekowitz | Director | Buy | +13,319 | +$92.27K |
| 2025-03-06 | Alan Ezekowitz | Director | Buy | +86,681 | +$515.93K |
| 2025-02-27 | Gil M Labrucherie | Chief Financial Officer | Buy | +10,000 | +$56.87K |
| 2025-02-27 | Jeffrey Finer | CEO and President | Buy | +17,000 | +$96.96K |
| 2025-02-26 | Third Rock Ventures V, L.P. | 10%+ Owner | Buy | +18,861 | +$113.15K |
| 2025-02-24 | Third Rock Ventures V, L.P. | 10%+ Owner | Buy | +1,040,342 | +$6.17M |
| 2025-02-21 | Gil M Labrucherie | Chief Financial Officer | Buy | +30,000 | +$172.30K |
| 2025-02-07 | Gil M Labrucherie | Chief Financial Officer | A | +222,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Third Rock Ventures V, L.P. | 10%+ Owner | 10,280,191 | $508.82M |
| RA Capital Nexus Fund III, L.P. | Director | 4,777,415 | $236.46M |
| Jeffrey Finer | Chief Executive Officer | 821,907 | $40.68M |
| Elizabeth Bhatt | President and COO | 174,209 | $8.62M |
| Uwe Klein | SVP, Biological Sciences | 127,533 | $6.31M |
| Alan Ezekowitz | Director | 117,420 | $5.81M |
| Daniel D. Long | SVP, Drug Discovery | 99,745 | $4.94M |
| Gil M Labrucherie | Chief Financial Officer | 40,000 | $1.98M |
| Samira Shaikhly | Chief People Officer | 793 | $39.25K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SEPN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.